Category: ACN Newswire

- Annual sales of HuaTangNing exceeded 4 million packs, a year-on-year increase of 91%, with revenues reaching RMB 492.9 million, a year-on-year increase of 93%, marking outstanding results from the Company’s fully independent commercialization operation.- Delivered record financial performance, with profit before tax reaching RMB 1,106.4 million; maintained a robust bank balance and cash position of RMB 1,092.3 million at year-end, laying a solid foundation for sustainable operations and growth.- Gross margins rose to 56.9%, and selling expenses as a percentage of revenue were optimized to 33.6% from 59.9%, significantly enhancing profitability.- HuaTangNing renewed its listing in the new National Reimbursement Drug List (NRDL) at the same price in 2025 for the calendar years 2026 and 2027, reaffirming its clinical and innovative value.- With the approval of PTE, market exclusivity in China granted another 5 years to April 2034, further strengthening commercial certainty.- Dorzagliatin was approved for commercialization in Hong Kong as HYHOMSIS®, accelerating its global expansion toward South-East Asia.- Multiple real-world evidence published to demonstrate therapeutic advantage of dorzagliatin.- Continuous expansion of therapeutic potential of glucose homeostasis and initiation of new first-in-disease indications study covering diabetes prevention, rare diseases, mild cognition impairment and frailty.SHANGHAI, Mar 27, 2026 - (ACN Newswire) – Hua Medicine ("the Company", Hong Kong Stock Exchange Stock Code: 2552) announces the audited consolidated results of the Company and its subsidiaries for the year ended December 31, 2025 (the “Reporting Period”). During the Reporting Period, the commercialization of HuaTangNing (dorzagliatin tablets), the Company’s core product – the global first-in-class innovative anti-diabetes medicine, glucokinase activator (GKA) – advanced comprehensively across all fronts, the Company’s independent commercialization team was efficiently and seamlessly established in its first year of operations, the Company’s R&D pipeline continued to be enriched, and the Company’s financial performance achieved a historic breakthrough, successfully entering a new stage of profitability, injecting strong momentum into the innovative development of the global diabetes treatment field.Dr. Li CHEN, Founder and CEO of Hua Medicine, stated: “2025 is a remarkable year in the commercialization operation of Hua Medicine. The Company has successfully advanced from R&D to commercialization driven organization and achieved the fully independent capacity in commercialization of global first in class novel glucose homeostasis regulator HuaTangNing. With strong market execution and product competitiveness, we have achieved nearly triple-digit growth in sales volume and revenue over 2024 when the commercialization was farmed out to sales and marketing partners. At the same time, the Company has made key progress in global market expansion through registration of drozagliatin in Hong Kong and position it toward 700 M population in south-east Asia. We continue to expand the clinical application of glucose homeostasis regulation technology and engage in new indications such as early-stage Alzheimer’s disease and Frailty. The first-in-disease efforts in GCK-MODY and Frailty set the new innovation course of Hua Medicine in the next 5 years.” Business Highlights and Operational Progress- Fully Powered Commercialization, Historic Breakthrough in ProfitabilityOn January 1, 2025, the Company assumed full responsibility for the commercialization of HuaTangNing, allowing the company to consolidate both operational and strategic control over market execution in China. The Company successfully built a professional sales team covering 10 sales regions around the country, focusing on marketing, medical affairs and commercial operation. Through an AI-empowered digital commercialization platform, operational efficiency and sales productivity were greatly enhanced, injecting new vitality into the Company’s commercial development.Reimbursement coverage under the NRDL has significantly increased accessibility, especially in Tier 2 and Tier 3 hospitals, and played a critical role in accelerating patient adoption. Since its launch in October 2022, HuaTangNing has been prescribed to over 500,000 patients through 3,000+ hospitals, community centers, pharmacies and online channels.Sales performance exceeded expectations, with 4.011 million packs of HuaTangNing sold during the reporting period, representing a 91% increase over the fiscal year 2024. This growth was achieved at the same price for both periods, underscoring strong demand and successful execution of Hua’s commercial strategy.In terms of profitability, the Company’s gross profit reached approximately RMB280.4 million, a year-on-year increase of 125%. Thanks to expanded production scale and optimized manufacturing processes, the Company’s gross margin improved to 56.9%, increasing by 8.2 percentage points as compared to 48.7% for the year of 2024. Selling expenses increased only by RMB12.3 million to RMB165.5 million, reflecting a significant positive trend towards profitability when our selling expenses in the 2025 fiscal year represents only 33.6% of revenue, whereas in the 2024 fiscal year, our selling expenses represented approximately 59.9% of revenue. In fiscal year 2025, our commercialization efforts achieved profits of approximately RMB114.9 million (as defined by gross profits less selling expenses). Although we expect to continue to increase personnel to our commercialization team, we expect this profitability trend in our commercial operations in mainland China to continue.Following the termination of the collaboration with Bayer at the end of 2024, dorzagliatin achieved a record-high sales volume. Profit before tax increased to RMB1,106.4 million for the fiscal year 2025. We ended fiscal year 2025 with a cash position of approximately RMB1,092.3 million.- Accelerated Global Layout, Strengthened Core Rights and InterestsThe Company took a key step in global expansion. On February 27, 2026, dorzagliatin (trade name: MYHOMSIS®, was successfully approved for marketing by the Hong Kong regulatory authority. The Company plans to officially launch the product in the Hong Kong market by the middle of 2026 and further expand to Asian regions. In addition, the Company submitted a new drug registration application in Macau in 2025.The Company also made new progress in intellectual property protection. In February 2026, the patent term extension (PTE) application for dorzagliatin was formally approved by the China National Intellectual Property Administration, thereby the core patent protection period of dorzagliatin extended to April 2034 and an additional 5-year market exclusivity obtained, which provides a strong guarantee for the product’s long-term market competition.In 2025, dorzagliatin was recognized as national innovation and an effective therapy for chronic diseases by the regulatory authorities in China. Accordingly, the same NRDL price was offered for the calendar years 2026 and 2027. Reimbursement coverage under the NRDL has significantly increased accessibility, especially in Tier 2 and Tier 3 hospitals, and played a critical role in accelerating patient adoption. The Company will continue to safeguard the product’s market competitiveness and patient accessibility and accelerate the popularization of the drug among patients.- Advancement of Real-World Studies, Continuous Validation of Clinical ValueReal-world evidence (RWE) studies continue to corroborate the key role of dorzagliatin in improving glucose-dependent pancreatic islet secretion function, and demonstrate its efficacy in diabetes prevention, remission, and delaying or preventing diabetes complications.The RWE study sponsored by Hua Medicine HMM0701 with 380 T2D patients was fully enrolled in 2025. The interim analysis, as reported at the 2025 American Diabetes Association (ADA), showed that 86% of such patients were taking two or more antidiabetic drugs and 41% of such patients were using insulin. After a 6-month treatment, a significant improvement of glycemic control was observed with HbA1c reduction from 8.1% to 7.3% with the mean time-in-range (TIR) levels increasing to over 70%. Thus far, the studies have demonstrated that when dorzagliatin is administered in combination with other antidiabetic drugs, such patients have experienced significantly improved post-meal glucose levels and improved β-cell function.Separately, a mechanistic study with dorzagliatin (employing double-tracer measurement) was conducted in the United States to provide scientific evidence of hepatic glycogen formation in T2D patients with an average of 17 years of diagnosed diabetes. In this study, patients were treated with dorzagliatin twice daily for 6 weeks. The results showed that dorzagliatin increased direct glucose flux to hepatic glycogen implying the improvement of restoration of hepatic Glucokinase (GK) function. Together with the clinical research data that dorzagliatin improves early phase insulin release and GLP-1 secretion, recovery of hepatic glycogen synthesis in T2D patients offers an important path in controlling post-meal glucose excursion and provides a unique opportunity in controlling diabetes complications, such as diabetes kidney diseases and mild cognition impairment.The RWE sponsored by Hua Medicine (HMM0601) has completed clinical trials with over 2,000 subjects, with average diabetes duration of 7.9 years and above 30% having disease duration more than 10 years. The initial results suggest that dorzagliatin is safe and well tolerated in Chinese T2DM patients. There were no new adverse effects observed in the study and the incident rate remains as low as what was observed in Phase III clinical trials. Patient adherence was generally high, with a mean adherence rate of approximately 95%. In this study, 80% of the participants have used one or more oral anti-diabetes medicine, and 20% used insulin. Dorzagliatin demonstrated good efficacy and safety not only in the overall population but also in elderly, obese, and hyperglycemic patient populations, whether used as monotherapy or in combination with metformin, SGLT2 inhibitors, insulin, and other medications. The topline results will be reported at the 2026 American Diabetes Association.- Deepened Clinical R&D, Continuous Expansion of New IndicationsNew Indication for Dorzagliatin – MODY-2 Patients.Medical experts in mainland China and Hong Kong have conducted independent clinical and preclinical studies of dorzagliatin for MODY-2 treatment. MODY-2, also called GCK-MODY, is a monogenic disease in which patients have a genetic defect of glucokinase gene (GCK) which results in elevated blood glucose and significant reduction of the second phase insulin secretion. The population of GCK-MODY patients is approximately 1.7 million in China. These patients are diagnosed with diabetes at a young age and represent an unmet medical need given that currently available medications are not effective. In clinical studies with MODY-2 patients, China investigators have reported that dorzagliatin is effective in reducing blood glucose levels to normal levels in MODY-2 patients who previously failed to manage their elevated blood glucose levels when treated with metformin, TZD, DPP-IV inhibitors, and SGLT-2 inhibitors. Additional results demonstrated that a single dose of dorzagliatin improved overall glucose sensitivity and second phase insulin secretion significantly in GCK-MODY patients, suggesting a unique mechanism of action of dorzagliatin to regulate GLP-1 secretion. Based on such results, Hua Medicine has communicated and reached a consensus with the CDE at NMPA to file the IND submission of dorzagliatin for MODY-2 patients in 2026.Dorzagliatin for Diabetes Prevention.Prevention of diabetes is an important focus at Hua Medicine. There are approximately 1.12 billion people living with prediabetes worldwide. We have initiated SENSITIZE 3 clinical study in Hong Kong in pre-diabetic (IGT) subjects and in early diabetes patients. These studies represent first-in-disease studies. In this double-blinded placebo-controlled study, we will evaluate the blood glucose management and pancreatic function under IVGTT and OGTT conditions to better define the clinical treatment baseline and endpoints. We expect to complete this study in 2026 and explore the opportunity to file IND applications of dorzagliatin for diabetes prevention in China and Asian Pacific regions thereafter. Dorzagliatin for Neurodegenerative Diseases.MCI shows approximately 15.5% prevalence among elderly people in China and approximately 22% in the US, and is common in T2D patients with a 45% incidence rate. The development of dorzagliatin for neurodegenerative disease is a new focus in our drug discovery efforts. Through the Genome-Wide Association Study (GWAS) and Mendelian Randomization (MR) study, we have realized the important role of GCK gene activation in the prevention of memory loss and cognitive impairment in humans. It has also come to our attention that post-meal glucose excursion is closely related to Alzheimer disease and dementia. The bio-energy balance in the brain is largely dependent on the glucose homeostasis control in the peripheral organ and the neural network communication in the central and peripheral system via spatial temporal management. Impaired glucose homeostasis and diabetes conditions result in a reduction of glucose transporter expression and insulin receptor expression in the brain, which can be prevented by low dose dorzagliatin. We have realized the potential of dorzagliatin in the treatment of mild cognitive impairment (MCI) and will initiate these first-in-disease clinical studies in the future.Dorzagliatin for Frailty.Frailty is an age-related geriatric syndrome characterized by reduced tolerance to internal and external stressors. Approximately 17% of Americans and 11% of Asians over the age of 50 suffer from frailty, while pre-frailty affects roughly 50% and 47% of these populations, respectively. It is not a single-organ disease, but the consequence of dysregulated multisystem homeostasis. Genetic evidence supports the causal effects of glucokinase (GK) activation on lowering frailty risk. We plan to initiate clinical studies in the future to advance dorzagliatin’s application in frailty.Development of combination therapy for diabetes and complications.Dorzagliatin rescues pancreatic function in glucose insulin secretion and GLP-1 secretion, as evidenced by clinical and basic research results. It also improves hepatic insulin sensitivity and reduces hepatic insulin resistance through recovery of hepatic glycogen synthesis in T2D patients. The combination of dorzagliatin with DPP-IV inhibitors, SGLT-2 inhibitors, and GLP-1 agonists have demonstrated effective regulation of lipid metabolism. Studies in combination with anticancer PI3K inhibitors have also offered unique benefits for glucose homeostasis management.- Diversified Product Pipeline, Innovative Layout for Future GrowthHua Medicine continues to enrich its pipeline layout based on core products. The Company has accelerated the R&D of a fixed-dose combination (FDC) of dorzagliatin and metformin as a twice-daily therapy for Type 2 diabetes patients with inadequate glycemic control on metformin alone, to further improve patient medication compliance. The product is supported by the strong results of the loose-dose combination in both Phase III clinical trials and real-world use. The Company has submitted an IND application to NMPA, and the GMP commercial manufacturing process has been successfully carried out, preparing for the pivotal bioequivalence study for NDA filing in 2027. Clinical studies have shown that the combination of dorzagliatin and metformin can better control blood glucose, reduce postprandial blood glucose and improve fasting blood glucose, providing new clinical value for optimizing blood glucose homeostasis endpoints.We have advanced our 2nd generation GKA as a once daily therapy for patients with obesity, leveraging dorzagliatin effects in improved glucose-stimulated GLP-1 secretion in the pancreas and in the intestine. The MAD study of the 2nd generation GKA was initiated in the United States with first-patient-in in December 2025, and we expect to report topline data by the middle of 2026.Meanwhile, the Company is also exploring combination therapy regimens of dorzagliatin with GLP-1 receptor agonists, SGLT-2 inhibitors and other drugs. In a recently published clinical trial in China, researchers reported the superior benefits of our dorzagliatin in combination with semaglutide as compared to semaglutide alone in a 12-week study. The combination group showed superior results across several key measures, including glycemic control, bodyweight related indicators and β-cell function.Financial Summary- Revenue generated by the Company was approximately RMB 492.9 million from the sale of approximately 4.011 million packs of HuaTangNing, increases of approximately 93% and 91% respectively, as compared with the year ended December 31, 2024.- Gross profit generated by the Company for the year ended December 31, 2025, was approximately RMB280.4 million, representing an increase of approximately 125%, as compared with the year ended December 31, 2024, and gross margins rose to 56.9%.- Profit before tax increased by approximately 542% to approximately RMB1,106.4 million for the year ended December 31, 2025, as compared with the year ended December 31, 2024.- Bank balances and cash position was approximately RMB1,092.3 million as of December 31, 2025.- Expenditures incurred by the Company for the year ended December 31, 2025, were approximately RMB433.4 million.Forward-Looking StatementsThis document contains statements regarding Hua Medicine's and its products' future expectations, plans and prospects. Such forward-looking statements relate only to events or information as of the date on which the statements are made in this document and are subject to change in light of future developments. Except as required by law, the Company shall not be obligated to update or publicly revise any forward-looking statements or unforeseen events after the date of such statements, whether as a result of new information, future events or other circumstances. Please read this document carefully and understand that actual future performance or results of the Company may differ materially from expectations due to various risks, uncertainties or other statutory requirements.About Hua MedicineHua Medicine (The “Company”) is an innovative drug development and commercialization company based in Shanghai, China, with companies in the United States and Hong Kong. Hua Medicine focuses on developing novel therapies for patients with unmet medical needs worldwide. Based on global resources, Hua Medicine teams up with global high-calibre people to develop breakthrough technologies and products, which contribute to innovation in diabetes care. Hua Medicine's cornerstone product HuaTangNing (dorzagliatin tablets), targets the glucose sensor glucokinase, restores glucose sensitivity in T2D patients, and stabilizes imbalances in blood glucose levels in patients. HuaTangNing was approved by the National Medical Products Administration (NMPA) of China on September 30th, 2022. It can be used alone or in combination with metformin for adult T2D patients. For patients with chronic kidney disease (CKD), no dose adjustment is required. It is an oral hypoglycemic drug that can be used for patients with Type 2 diabetes with renal function impairment. In February 2026, dorzagliatin (Trade name: MYHOMSIS®,) was approved for marketing by the Pharmaceutical Services of the Department of Health of the Government of the Hong Kong Special Administrative Region of China.For more informationHua MedicineWebsite: www.huamedicine.comInvestorsEmail: ir@huamedicine.comMediaEmail: pr@huamedicine.com Copyright 2026 ACN Newswire. All rights reserved. www.acnnewswire.com

- 华堂宁(R)全年銷量超400萬盒，同比增長91%，銷售額達4.929億元，同比增長93%，公司全面自主商業化運營成效卓著。- 實現創紀錄盈利，稅前盈利達11.064億元；現金餘額穩健，截至年末達 10.923億元，為持續運營發展奠定堅實基礎。- 毛利率提升至56.9%，銷售開支占比從59.9%優化至33.6%，盈利能力顯著增強。- 华堂宁(R)原價續約新版醫保目錄，2026-2027年維持2025年的價格不變，臨床價值和創新價值再獲認可。- 隨著PTE獲批，中國市場獨佔權獲5年延期至2034年4月，商業確定性進一步提升。- 多格列艾汀（HYHOMSIS(R) ，華領片(R)）獲得香港地區上市批准，加速其面向東南亞的全球擴張進程。- 發佈多項真實世界證據，證實多格列艾汀治療優勢。- 持續拓展血糖穩態治療潛力，啟動多項全新的疾病首創新適應症研究，研究範圍涵蓋糖尿病預防、罕見病、輕度認知障礙及衰弱症領域。上海, 2026年3月27日 - (亞太商訊) - 華領醫藥（「公司」，香港聯交所股份代號：2552）宣佈公司及其附屬公司截至2025年12月31日止年度（「報告期」）經審核的綜合業績。報告期內，公司核心產品、全球首創抗糖尿病新藥、葡萄糖激酶激活劑（GKA）华堂宁(R)（多格列艾汀片）實現全方位推進，公司自主商業化團隊於運營首年即實現高效組建和運轉，研發管線持續豐富，財務表現實現歷史性突破，成功邁入盈利新階段，為全球糖尿病治療領域的創新發展注入強勁動力。華領醫藥創始人、CEO陳力博士表示：「2025年是華領醫藥商業化運營中的意義非凡的一年。公司成功完成從研發驅動型組織向商業化驅動型組織的轉型，具備了全球首創新藥、血糖穩態調節劑华堂宁(R)的完全自主商業化運營能力。憑藉強勁的市場執行力與產品競爭力，相較於2024年將商業化業務委託給營銷合作夥伴的階段，公司的銷量與營收實現了近三位數的增長。與此同時，通過推動多格列艾汀在香港的註冊工作，公司在全球市場拓展方面取得了關鍵性進展，我們將向覆蓋7億人口的東南亞地區進行市場佈局。我們持續拓展血糖穩態調控技術的臨床應用場景，積極佈局早期阿爾茨海默病、衰弱症等新適應症領域。針對GCK-MODY及衰弱症開展的疾病首創新藥研發工作，將為華領醫藥未來五年的創新發展劃定全新方向。」業務亮點與運營進展- 商業化全面發力，盈利實現歷史性突破2025年1月1日起，公司正式全面接管华堂宁(R)在中國的商業化工作，獲得全部運營與戰略主導權，公司成功搭建了專業的銷售團隊，覆蓋全國10個銷售區域，專注於產品營銷、醫學事務及商業運營。通過人工智能賦能的數字商業化平台，運營效率與銷售生產力大幅提升，為公司商業化發展注入新活力。受益於國家醫保藥品目錄的持續廣泛覆蓋，华堂宁(R)在二級和三級醫院的處方量顯著增長，患者可及性不斷提高，通過3000多家醫院、社區衛生中心、藥房和線上渠道，惠及超過50萬名患者。報告期內，產品銷量達401.1萬盒，同比增長91%；銷售額達4.929 億元，同比增長93%，在單價保持穩定的情況下，充分印證了市場需求的強勁增長和自主商業化團隊的高效執行能力。盈利能力方面，2025年，公司毛利達到2.804億元，同比增長125%，得益於生產規模擴大及製造工藝優化，公司毛利率從2024年的48.7% 提升至56.9%，增加8.2個百分點；銷售開支僅增長1230萬元至1.655億元，占收入比例優化至33.6%，較2024年的59.9%大幅下降；商業化業務實現約1.149億元盈利（按毛利扣除銷售開支計算）。公司預期仍將持續擴充商業化團隊規模，但商業化運營的盈利趨勢也將持續增長。在2024年底終止與拜耳合作後，多格列艾汀銷售額創歷史新高，報告期內，公司稅前盈利增加至人民幣11.064億。截至2025年末，現金結餘約為人民幣10.923億元，穩健的現金情況為公司持續發展奠定了堅實基礎。- 全球佈局加速推進，核心權益得到強化公司全球化佈局邁出關鍵步伐。2026年2月27日，多格列艾汀（香港地區商品名：MYHOMSIS(R)，華領片(R)）成功獲得香港監管機構的上市批准，公司計劃2026年中正式在香港市場推出該產品，並將進一步向亞洲地區拓展。此外，公司已于2025年向澳門藥監局遞交華領片(R)（MYHOMSIS(R)）的新藥上市申請。公司在知識產權保護方面也再獲進展。2026年2月，中國國家知識產權局批准多格列艾汀專利期限補償（PTE）申請，核心專利保護期延長至2034年4月，新增5年市場獨佔權，為產品長期市場競爭提供有力保障。2025年，多格列艾汀獲中國監管機構認定為國家級創新藥及慢病有效治療藥物，國家醫保局已確認，2026-2027年，华堂宁(R)的國家醫保目錄價格維持不變，公司將持續保障產品的市場競爭力和患者可及性，尤其在二級和三級醫院，加速患者的用藥普及。- 真實世界研究推進，臨床價值獲持續驗證真實世界證據（RWE）研究持續佐證多格列艾汀在葡萄糖依賴性胰島分泌功能改善中的關鍵作用，並顯示其在糖尿病預防、緩解及延緩或預防糖尿病併發症方面的功效。HMM0701已完成入組，共招募380名2型糖尿病患者。2025年6月，在美國ADA年會上發表的中期分析結果顯示，86%的患者同時服用兩種或以上降血糖藥物，41%的患者使用胰島素。經6個月治療後，血糖控制明顯改善，糖化血紅蛋白由8.1%降至7.3%，平均TIR（目標範圍內時間）提升至70%以上。迄今為止的研究顯示，多格列艾汀與其他降糖藥物聯合使用時，患者的餐後血糖水平和β細胞功能均顯著改善。另外，在美國進行的多格列艾汀機制研究（採用雙示蹤劑測量法），為平均確診糖尿病17年的2型糖尿病患者的肝糖原生成提供了科學證據。在該研究中，患者每日服用兩次多格列艾汀，持續6周。結果顯示，多格列艾汀能增加葡萄糖直接流入肝糖原的通量，意味著其有助於恢復肝臟GK功能。結合臨床研究數據顯示，多格列艾汀可改善早期胰島素釋放和GLP-1分泌，恢復2型糖尿病患者的肝臟GK功能，不僅為控制餐後血糖波動提供重要途徑，並在控制糖尿病併發症（如糖尿病腎病變及輕度認知障礙）方面提供獨特契機。HMM0601研究已經完成臨床試驗，共納入2000名受試者，平均患病時間為7.9年，其中超過30%患病時間超過10年。初步結果顯示，多格列艾汀在中國2型糖尿病患者中安全性、耐受性良好。研究中未觀察到新的不良反應，不良反應發生率維持在III期臨床試驗中觀察到的低水平，患者的用藥依從性普遍較高，平均依從率約為95%。在本研究中，80%的受試者已使用一種或多種口服降血糖藥，20%的受試者使用胰島素。多格列艾汀不僅在整體患者群體中展現出良好的療效及安全性，在老年、肥胖及高血糖患者群體中同樣有效，無論作為單藥治療或與二甲雙胍、SGLT-2抑制劑、胰島素及其他藥物聯合使用。頂線結果將於2026年ADA年會上發表。- 臨床研發持續深化，新適應症不斷拓展多格列艾汀用於治療MODY-2患者。中國內地及香港地區醫學專家已獨立開展多格列艾汀用於MODY-2治療的臨床研究及臨床前研究。MODY-2（又稱GCK-MODY）是一種單基因疾病，患者因葡萄糖激酶基因(GCK)存在遺傳缺陷，導致血糖升高及第二時相胰島素釋放顯著減少。在中國，MODY-2患者群體規模約為170萬人。此類患者確診糖尿病時年齡偏小，且由於現有治療藥物療效不佳，這一患者群體存在未被滿足的醫療需求。中國研究人員在針對MODY-2患者的臨床研究中報告指出，對於先前使用二甲雙胍、TZD、DPP-4抑制劑及SGLT-2抑制劑仍無法控制高血糖的MODY-2患者，多格列艾汀能有效將血糖降至正常水平。其他結果顯示，單劑量多格列艾汀可顯著改善這類患者的整體葡萄糖敏感性及第二時相胰島素分泌，表明多格列艾汀具有調節GLP-1分泌的獨特作用機制。基於以上結果，華領醫藥已與國家藥品監督管理局（NMPA）藥品審評中心溝通，將於2026年提交多格列艾汀用於MODY-2患者的IND申請。多格列艾汀用於糖尿病預防。糖尿病預防是華領醫藥的重要研發重點。公司已於香港啟動針對糖尿病前期糖耐量異常（IGT）受試者及早期糖尿病患者的SENSITIZE 3臨床研究。這項雙盲安慰劑對照研究將評估受試者在靜脈葡萄糖耐量試驗及口服葡萄糖耐量試驗下的血糖控制及胰島功能，以更明確界定臨床治療基線及終點指標。我們預計於2026年完成研究後，將在中國及亞太地區探索提交多格列艾汀用於糖尿病預防的IND申請的新機遇。多格列艾汀用於神經退行性疾病。研究顯示，中國老年人的輕度認知障礙患病率約為15.5%，美國則約為22%；該症狀在2型糖尿病患者中也相當常見，發病率達45%。多格列艾汀用於神經退行性疾病的研究已成為公司藥物研發工作的新焦點。通過全基因組關聯分析(GWAS)及孟德爾隨機化（MR）研究，我們發現GK基因激活在預防人類記憶力衰退及認知障礙方面具有重要作用。同時我們也發現，餐後血糖波動與阿茲海默症及失智症密切相關。血糖穩態異常及糖尿病狀況會導致大腦葡萄糖轉運蛋白及胰島素受體表達減少，而低劑量多格列艾汀可預防該功能損傷。我們已確認多格列艾汀在治療輕度認知障礙方面的潛在價值，並將於未來啟動針對該疾病領域的首創療法的相關臨床研究。多格列艾汀用於治療衰弱症。衰弱症是一種與年齡相關的老年綜合症，其特徵為對內外應激因子的耐受性降低。約17%的美國人及11%的亞洲人（50歲以上）患有衰弱症，而處於衰弱症前期者則分別約占此兩個群組的50%及47%。衰弱症並非單一器官疾病，而是多系統內穩態失調所導致的後果。遺傳學證據支持GK激活對降低衰弱症風險具有因果作用。我們計劃於未來啟動臨床研究，以推進多格列艾汀在衰弱症治療領域的應用。聯合用藥用於糖尿病及併發症的治療。臨床與基礎研究結果顯示，多格列艾汀能恢復胰腺在葡萄糖刺激下的胰島素及GLP-1分泌，也可以通過恢復2型糖尿病患者肝臟葡萄糖激酶功能，改善肝臟胰島素敏感性並降低肝臟胰島素抵抗。多格列艾汀與DPP-4抑制劑、SGLT-2抑制劑及GLP-1受體激動劑的聯合使用已證明可有效調節脂質代謝，與抗癌PI3K抑制劑聯合使用的研究也為血糖穩態管理帶來獨特優勢。- 產品管線豐富多元，創新佈局未來增長華領醫藥在核心產品基礎上持續豐富管線佈局。依託多格列艾汀與二甲雙胍聯合用藥在III期臨床試驗和真實世界應用中取得的優異數據，公司加速推進多格列艾汀與二甲雙胍固定複方製劑（FDC）的研發。該製劑為每日兩次給藥方案，適用于單用二甲雙胍血糖控制不佳的2型糖尿病患者，旨在以進一步提升患者的用藥依從性。公司已向NMPA提交IND申請文件。此外，GMP商業化生產工藝也已成功開展，為2027年新藥上市申請的關鍵生物等效性研究做好準備。臨床研究顯示，多格列艾汀與二甲雙胍聯用能夠更好地控制血糖，降低餐後血糖，改善空腹血糖，為優化血糖穩態終點提供了新的臨床價值。第二代GKA的研發取得重要突破。作為肥胖2型糖尿病患者每日一次治療的緩釋新片劑，公司已在美國啟動多格列艾汀多劑量遞增（MAD）研究，以探討第二代GKA在血糖穩態控制方面的療效及新藥的作用機制，首例患者已於2025年12月入組，預計2026年中公佈頂線數據。同時，公司還在探索多格列艾汀與GLP-1受體激動劑、SGLT-2抑制劑等藥物的聯合治療方案。近期，在一項中國的臨床試驗中，研究者報告：多格列艾汀聯合司美格魯肽治療12周，療效顯著優於司美格魯肽單藥治療。聯合治療組在血糖控制、體重相關指標及β細胞功能等多項關鍵指標上均表現更優。財務摘要截至2025年12月31日，- 华堂宁(R)全年銷量約401.1萬盒，相較2024年全年，同比增長91%，實現營收約4.929億元，同比增長93%。- 毛利約人民幣2.804億元，同比增長125%，毛利率提升至56.9%；- 稅前盈利約人民幣11.064億元，較2024年增長542%；- 銀行結餘及現金約人民幣10.923億元，資金狀況穩健；- 總開支約人民幣4.334億。前瞻性聲明本文包含有關華領醫藥以及產品未來預期、計劃和前景的陳述。該等前瞻性陳述僅與本文作出該陳述當日的事件或資料有關，可能因未來發展而出現變動。除法律規定外，於作出前瞻性陳述當日之後，無論是否出現新資料、未來事件或其他情況，我們並無責任更新或公開修改任何前瞻性陳述及預料之外的事件。請仔細閱讀本文並理解，由於各種風險、不確定性或其他法定要求我們的實際未來業績或表現可能與預期有重大差異。關於華領華領醫藥（「本公司」）是一家總部位於中國上海的創新藥物研發和商業化公司，在美國、中國香港設立了公司。華領醫藥專注於未被滿足的醫療需求，為全球患者開發全新療法。華領醫藥彙聚全球醫藥行業高素質人才，融合全球創新技術，依託全球優勢資源，研究開發突破性的技術和產品，引領全球糖尿病醫療創新。公司核心產品华堂宁(R)（多格列艾汀片）以葡萄糖傳感器葡萄糖激酶為靶點，提升2型糖尿病患者的葡萄糖敏感性，改善患者血糖穩態失調。2022年9月30日，华堂宁(R)已獲得中國國家藥品監督管理局（NMPA）的上市批准，用於單獨用藥或者與二甲雙胍聯合用藥，治療成人2型糖尿病。對於腎功能不全患者，無需調整劑量，是一款可用於腎功能損傷的2型糖尿病患者的口服降糖藥物。2026年2月，多格列艾汀（商品名：MYHOMSIS(R)，華領片(R)）獲得中國香港特別行政區政府衛生署藥物辦公室的上市批准。詳情垂詢華領醫藥網址：www.huamedicine.com投資者電郵：ir@huamedicine.com媒體電郵：pr@huamedicine.com新聞免責聲明本材料，如為上下文論述的準確性和完整性，提及在中國上市的產品相關信息的，特別是標識或要求，應遵循中國監管機構批准的相關文件。另外，相關信息不應被解讀為對任何藥物或者診療方案的推薦或者宣傳，亦不應替代任何醫療衛生專業人士的醫療建議，涉及醫療的相關事宜務必諮詢醫療衛生專業人士。 Copyright 2026 亞太商訊. All rights reserved. www.acnnewswire.com

香港, 2026年3月27日 - (亞太商訊) - 3月26日，雲知聲（09678.HK）發佈截至2025年12月31日止年度的經審核全年業績，展現上市後首份成績單強勁的增長動能與持續優化的財務結構。營收結構持續優化，下半年增長提速2025年全年，雲知聲實現總營收12.1億元人民幣，同比增長29%。其中，下半年收入同比增長33%，達8.1億元。值得關注的是，公司大模型業務全年收入6.1億元，同比增長超10倍。尤其是下半年，該業務貢獻收入約5億元，為上半年規模的5倍，顯示出強勁的規模化落地能力。虧損大幅收窄，盈利路徑日漸清晰在營收高速增長的同時，公司虧損狀況顯著改善。2025年下半年，公司淨虧損同比收窄84%，經調整後虧損同比收窄92%，接近盈虧平衡點，反映出公司在成本控制與運營效率方面的持續優化。同時，公司的部分經營指標也得到明顯改善。經調整營業費用率較去年同比大幅下降10%，銷售費用不升反降，佔收入比重僅為5.4%，費效比提升明顯。從數據端來看，2025年公司人均產值為252萬元/人，相較24年的202萬元同比增長25%，人均創效能力持續領跑行業，直觀彰顯了公司技術驅動、精益運營的核心優勢。雙輪驅動戰略落地，智慧醫療與智慧生活齊頭並進2025年，在技術突破與政策紅利的雙重驅動下，全球人工智能市場需求持續升溫。雲知聲堅持「強基模+深應用」戰略，持續夯實全模态技術底座，推動自研大模型矩陣在醫療、語音、OCR等領域的全球影響力不斷提升。在商業化層面，公司以AI原生組織推動業務落地，智慧醫療與智慧生活雙輪驅動戰略成效顯著。報告期內：智慧生活業務實現收入9.68億元，同比增長30.8%。其中，智慧交通業務同比增長近40%，目前，已在青島、寧波、深圳、南寧等10餘個城市落地基於山海大模型的智能體應用。此外，AI芯片累計出貨量突破1.1億顆，進一步驗證公司在終端AI產品的規模化能力。智慧醫療業務實現收入2.44億元，同比增長22.3%，客單價同比增長53.2%。2025年，合作的醫院中超70%為三級醫院，且超過三分之一客戶已經連續合作三年以上；而基於醫療大模型的病歷錄入與生成產品已在某頭部三甲醫院單院區實現全年病歷生成同比增長10倍；商業保險智能體平台案件處理量同比增長37倍；與頭部保險集團的深度合作中，控費率水平有效提升至約20%，相較傳統審核方式實現超10億元級別的增量成本管控，全面賦能保險機構在醫療風控領域的精細化運營。持續加碼研發，夯實技術護城河為鞏固行業領先地位，2025年公司持續在技術端大力投入，全年研發費用超3.8億元，佔經調整三費的75%；研發人員佔比達69%。持續的研發投入在多個技術領域取得突破，如在MedBench 4.0評測中，公司一舉斬獲「醫療智能體」「醫療大語言模型」「醫療多模态大模型」三項技術範式第一，榮膺「三冠王」。未來展望：深耕技術底座，拓展應用邊界展望未來，雲知聲將繼續深化「強基模+深應用」戰略。技術層面，公司將持續加大對基座大模型的戰略性投入，力爭保持全球一流水平；應用層面，將以MaaS（模型即服務）與智能體的規模化拓展為核心增長引擎，推動智慧生活與智慧醫療業務的指數級增長。同時，公司正積極探索以API調用、Token計費等模式構建經常性收入體系，並將C端產品機會作為第二增長曲線，進一步拓展商業化邊界。2026年第二季度，雲知聲將推出面向編程和辦公的原生智能體大模型，並預計能實現智能密度和Token生產效率的倍增。 Copyright 2026 亞太商訊. All rights reserved. www.acnnewswire.com

HONG KONG, Mar 27, 2026 - (ACN Newswire) – 26 March, Unisound (09678.HK) announced its audited annual results for the year ended December 31, 2025. As the Company's first annual results announcement since listing, it underscores strong growth momentum and continued improvement in its financial profile.Revenue Mix Continues to Improve, with Faster Growth in H2For the full year of 2025, Unisound achieved total revenue of $175 million, representing a year-on-year (YoY) increase of 29%. Revenue in the second half of the year increased by 33% YoY to $117 million.It is worth noting that the Company's large language model (LLM) business generated a full-year revenue of $88.43 million, surging by over 10 times YoY. In particular, this business contributed approximately $72.49 million in H2 revenue, five times the level recorded in H1, demonstrating a compelling capacity for large-scale commercial application.Losses Narrowed Significantly, Making the Path to Profitability Increasingly ClearAlongside the rapid revenue growth, the Company's losses improved markedly. In the second half of 2025, the Company's net loss narrowed by 84% YoY, and its adjusted loss narrowed by 92% YoY, approaching break-even. This reflects the Company's ongoing improvements in cost control and operational efficiency.Simultaneously, some of the Company's operating metrics saw marked improvement. The adjusted expense ratio declined significantly by 10 percentage points YoY, while selling expenses decreased rather than increased and accounted for only 5.4%, highlighting a clear improvement in cost-to-efficiency ratio. In 2025, revenue per employee reached $365,300, up 25% YoY from $292,900 in 2024. Employee productivity continued to lead the industry, clearly underscoring the Company's core strengths in technology-driven, lean operations.Dual-Engine Strategy Gains Traction, with AI in Healthcare and AI in Daily Life Advancing in TandemIn 2025, driven by both technological breakthroughs and policy tailwinds, global demand for AI continued to rise. Unisound adhered to its "Strong Foundation Model + Deep Application" strategy, continued to strengthen its multimodal technology foundation, and drove the continuous elevation of the global influence of its proprietary large model matrix in fields such as healthcare, speech, and OCR.On the commercialization front, the Company leveraged its AI-native organization to accelerate business execution, and its dual-engine strategy in AI in Healthcare and AI in Daily Life delivered notable results. During the reporting period:The AI in Daily Life business achieved revenue of $140 million, a YoY increase of 30.8%. Among this, the Transportation segment recorded nearly 40% YoY growth. At present, AI agent applications based on the Shanhai large model have been deployed in more than 10 cities, including Qingdao, Ningbo, Shenzhen and Nanning. In addition, cumulative AI chip shipments exceeded 110 million units, further validating the Company's scale capabilities in endpoint AI products.The AI in Healthcare business achieved revenue of $35.38 million, a YoY increase of 22.3%, with average revenue per customer growing by 53.2% YoY. In 2025, over 70% of the hospitals the Company collaborated with were tertiary hospitals, and more than one-third of customers had maintained continuous cooperation for over three years. The medical-record entry and generation products powered by the medical large model delivered a 10-fold YoY increase in full-annual medical record generation at a single campus of a leading Class III hospital. The commercial insurance AI agent platform recorded a 37-fold YoY increase in case processing volume. In deep cooperation with a leading insurance group, the expense control rate was effectively raised to approximately 20%, delivering more than $145 million in incremental cost management compared with traditional review methods, comprehensively empowering insurance institutions to refine their medical risk management operations.Continued R&D Investment Strengthens the Technology MoatTo consolidate its industry-leading position, the Company continued to invest heavily in R&D in 2025. Full-year R&D expenses exceeded $55.09 million, accounting for 75% of the Company's adjusted operating expenses, while R&D personnel accounted for 69% of the total workforce. This sustained investment drove breakthroughs across multiple technology areas. For example, in the MedBench 4.0 evaluation, the Company ranked first place in three technical paradigms: "Medical AI Agent," "Medical Large Language Model," and "Medical Multimodal Large Model," earning a "Triple Crown."Outlook: Deepening the Technological Foundation and Expanding Application BoundariesLooking ahead, Unisound will continue to deepen its "Strong Foundation Model + Deep Application" strategy. On the technological front, the Company will continue to increase strategic investment in foundational large models and strive to maintain a world-class level. On the application front, it will use the large-scale expansion of MaaS (Model-as-a-Service) and AI agents as its core growth engine, driving exponential growth in its AI in Daily Life and AI in Healthcare businesses. Meanwhile, the Company is actively exploring the establishment of a recurring revenue system through models such as API calls and Token-based billing, and regards opportunities in consumer-facing (C-end) products as a second growth curve to further expand its commercialization boundaries.Between Q2 and Q3 2026, Unisound will launch a native AI agent large model for programming and office applications, which is expected to double both intelligence density and token production efficiency. Copyright 2026 ACN Newswire. All rights reserved. www.acnnewswire.com

Financial HighlightsRMB 100 millionFor the 12 months ended 31 DecemberChange (%)20252024Revenue1566.111,776.64-11.85% Profit28.4265.53-56.64% Profit before Tax28.1665.95-57.30% Gross Profit194.95222.47-12.37% Gross Profit Margin12.45%12.52%-0.07pct Net Profit13.3741.95-68.12% Net Profit Attributable to Shareholders and Other Equity Holders2.2129.72-92.57% Net cash flows from operating activities 185.1492.6499.86% Dividend per share (RMB/share, tax inclusive)RMB 0.179RMB 0.176N/A Total dividend payout9.399.45-0.60% Performance Highlights1. Solid operating core segments with resilient high-quality development: In 2025, the Group achieved revenue of RMB 156.611 billion, net profit of RMB 1.337 billion, and maintained a gross profit margin of 12.45%, with a balanced domestic and overseas revenue structure.2. Dual improvement in cash flow and financial quality, with significantly enhanced risk resilience: Net cash flows from operating activities increased substantially by 99.86% to RMB 18.514 billion, while the cash and cash equivalents as of the end of the Year reached RMB 24.3 billion; the scale of interest-bearing debt decreased by RMB 4.7 billion year-on-year (“YoY”) to RMB 34.4 billion, and net interest expenses decreased by approximately RMB 730 million YoY, with the financial structure continuing to be optimized.3. Cash dividends and share buybacks implemented in parallel to reward investors: The Group proposes a cash dividend of RMB 0.179 per share (tax inclusive) for 2025. Together with multiple rounds of H-share and A-share buyback plans launched during the Year, the total proposed dividend and completed buybacks for 2025 amounted to RMB 1.852 billion.4. Significant improvement in profitability of energy-related businesses, becoming a key growth driver of the Group: Net profit of the offshore engineering segment and the financial and asset management segment (primarily drilling platform leasing) increased by approximately RMB 1.212 billion in total, while the energy, chemical and liquid food equipment segment increased by RMB 308 million. Among them, the gross profit margin of the offshore engineering segment increased significantly by 5.72 percentage points to 14.83%. Orders on hand for offshore engineering and energy, chemical and liquid food equipment reached US$5.09 billion and RMB 29.75 billion, respectively, with certain shipyards’ production schedules extending to 2030.5. Logistics-related businesses continued to serve as the Group’s “ballast stone”: During the Year, businesses such as container manufacturing and road transportation vehicles were affected by exchange rate fluctuations and cyclical changes, resulting in pressure on gross profit margins and profitability. However, the core segments remained solid, and the Group’s competitive advantages in the industry continued to be consolidated. Core products such as standard dry containers, reefer containers, tank containers and semi-trailers have maintained the world’s No.1 position for many consecutive years.6. Breakthroughs in both technology and orders in key businesses, with competitiveness highly recognised: In the high-end offshore engineering equipment sector, CIMC Raffles successfully developed the most complex products in the offshore industry, including FPSO/FLNG, becoming the only enterprise in China with dual-project EPCI general contracting capabilities; in the modular data center sector, the Group providing technical and manufacturing delivery services of prefabrication data center to industry customers exceeding 300MW, leading new transformation in computing power infrastructure.HONG KONG, Mar 26, 2026 - (ACN Newswire) – China International Marine Containers (Group) Co., Ltd. (“CIMC Group” or the “Group”, stock code: 000039.SZ/02039.HK) is pleased to announce the audited annual results for the 12 months ended 31 December 2025 (the “Year”).The Group’s management stated, “In 2025, profound global changes unseen in a century accelerated, and the global economy demonstrated resilience amid volatility. Positioned in an era of both opportunities and challenges, the Group closely adhered to the strategic theme of “accelerating the construction of new growth drivers and focusing on promoting high-quality development”. While stabilising its operating fundamentals, the Group further deepened its forward-looking strategic layout in the energy business and achieved fruitful results. For the year of 2025, the Group recorded revenue of RMB 156.61 billion and net profit of RMB 1.34 billion. Cash flows from operating activities increased significantly by 99.9% to RMB 18.51 billion, with the asset structure continuously optimized and risk resilience further enhanced.”In particular, to sincerely reward investors, CIMC Group proposes to distribute a cash dividend of RMB 0.179 per share (tax inclusive) to all shareholders for 2025, amounting to a total proposed cash dividend of RMB 939 million (tax inclusive). Meanwhile, the Group implemented share buybacks totalling RMB 913 million during 2025, bringing the combined total to RMB 1.852 billion.Segments Results (RMB 100 million)2025 Business indicatorsRevenueAs % of the total revenueGross profitAs % of the gross profitGross profit marginNet profitContainer manufacturing430.0927.46%57.5529.52%13.38%18.82Road transportationvehicles201.7812.88%32.0616.45%15.89%9.27Energy, chemical, and liquid food equipment271.9217.36%40.2420.64%14.80%10.40Offshore engineering179.3811.45%26.6013.65%14.83%10.57Logistics services267.9317.11%16.708.57%6.23%3.64Airport facilities and logistics equipment/fire safety and rescue equipment76.194.86%15.147.76%19.87%2.64Total of major segments1427.2991.12%188.2996.59%13.19%55.34Core Business Performance1. In logistics field:In the container manufacturing business, during the Year, despite negative supply chain factors such as U.S. tariff policies and geopolitical conflicts, global merchandise trade demonstrated strong resilience. Intra-regional trade, Asia-Europe routes and emerging market routes became the main drivers of incremental growth. Meanwhile, factors such as detours around the Red Sea, port congestion, environmental requirements in shipping and increasing complexity of trade routes reduced transportation efficiency, structurally boosting underlying demand and pushing the global container fleet into a new structural phase. As a result, overall demand for new containers in 2025 remained at a relatively high level, exceeding the average of the past decade. During the Year, the production and sales volume of the Group’s container manufacturing business declined YoY, in line with overall industry expectations, but the Group maintained its global No.1 position. Accumulated sales volume of dry cargo containers reached 2,224,900 TEUs (2024: 3,433,600 TEUs), representing a YoY decrease of 35.2%. Accumulated sales volume of reefer containers reached 208,200 TEUs (same period last year: 138,600 TEUs), representing a YoY increase of 50.2%. During the Year, the container manufacturing segment recorded revenue of RMB 43.009 billion, net profit of RMB 1.882 billion, and a slight decline in gross profit margin to 13.38%.In the logistics services business, during the Year, the segment recorded revenue of RMB 26.793 billion, representing a YoY decrease of 14.64%, and net profit of RMB 364 million, representing a YoY decrease of 16.65%, in line with industry trends. CIMC Wetrans actively adjusted its business structure and integrated resources. During the Year, self-sourced cargo volume increased by 6% YoY, while second-hand container trading and warehousing distribution in port logistics reached record highs. The industry logistics business focused on key sectors such as new energy, automotive and engineering projects to consolidate its niche advantages. In 2025, CIMC Wetrans ranked among the top five for three consecutive years in the “Comprehensive List of Freight Forwarding and Logistics Enterprises” published by the China International Logistics and Freight Forwarding Association.In the road transport vehicles business, during the Year, CIMC Vehicles recorded revenue of RMB 20.178 billion, representing a YoY decrease of 3.91%, and net profit of RMB 927 million, representing a YoY decrease of 14.29%. In the domestic market, the “Star-Chained Plan” reshaped the organisational and operational model, with revenue from the China semi-trailer business increasing by 14.65% YoY and gross profit margin increasing by 3.3%YoY. In overseas markets, the Global South markets maintained high-quality growth, with revenue reaching RMB 3.09 billion during the Reporting Period, representing a YoY increase of 17.7%, sales volume increasing by 29.1% YoY, and gross profit margin increasing by 1.3 percentage points YoY.The DTB business achieved steady growth in both sales volume and revenue, with a total of 28,570 units of mounted equipment products delivered, generating total revenue of RMB 3.184 billion, representing a YoY increase of 4.97%, with further improvement in market share of core products. Meanwhile, the Group continued to actively expand R&D and sales of new energy products, comprehensively building the EV-RT ecosystem and advancing the strategic development of pure electric tractors and trailers.In the airport facilities and logistics equipment/fire safety and rescue equipment, benefiting from the release and delivery of high-quality orders, the segment recorded revenue of RMB 7.619 billion during the Year, representing a YoY increase of 5.92%, and net profit of RMB 264 million. Airport equipment successfully delivered smart boarding bridges projects for Xi’an Xianyang International Airport, Antalya Airport in Türkiye and Lanzhou Airport, and secured major projects including Phase II of Nanning Airport and corridor projects at Hangzhou Airport T2 and T4 with its independently-developed innovative prefabricated fixed bridge solutions. Logistics equipment delivered automated three-dimensional warehouse systems for supporting the petrochemical and refining integration project in China. The fire safety and rescue equipment business advanced the overseas expansion of domestically manufactured products while focusing on frontier areas such as smart fire safety and unmanned fire trucks.2. In the Energy FieldIn the energy, chemical, and liquid food equipment business, the segment recorded revenue of RMB 27.192 billion, representing a YoY increase of 6.31%, and net profit increased significantly by 42.15% to RMB 1.040 billion. Among which, CIMC Enric recorded revenue of RMB 26.326 billion, representing a y YoY increase of 6.3%.Specifically, the clean energy segment advanced both offshore and onshore businesses, maintaining leading market share in key equipment such as high-pressure and cryogenic equipment, while capturing growth opportunities in natural gas applications in water and land transportation and power generation, and actively expanding into emerging markets for special industrial gas equipment in high-tech industries. In 2025, the segment secured new orders of RMB 22.229 billion, a record high. Among these, orders on hand for offshore clean energy-related business exceeded RMB 19 billion as of the end of 2025, with shipbuilding schedules extending to 2028. During the Year, the second coke oven gas comprehensive utilisation project — Linggang Phase I project — was successfully put into operation, and China’s first domestic mass-production bio-methanol (green methanol) project of CIMC Enric was completed and commenced operation. The chemical and environmental segment maintained its leading market share, while the medical equipment components and after-sales service businesses achieved steady growth. As of the end of 2025, orders on hand increased by 36.27% YoY to RMB 1.276 billion, providing strong support for future development. The liquid food segment maintained stable profitability, with gross profit margin increasing to 21.7% YoY.In the offshore engineering business, the Group’s core operating entity, CIMC Raffles, successfully achieved a strategic transformation from “manufacturing-led” to integrated “design + construction + integration” services, maintaining a leading position in the domestic market and emerging as an important new force in the international offshore engineering market. During the Reporting Period, the segment recorded revenue of RMB 17.938 billion, representing a YoY increase of 8.35%, and net profit of RMB 1.057 billion, becoming the Group’s second-largest profit contributor. Benefiting from the recovery of the global offshore engineering market, demand for high-end oil and gas equipment represented by FPSO/FLNG remained strong, while the industry accelerated its transition toward green and intelligent development, driving steady growth in new energy equipment orders. During the year, the Group secured new contract orders of US$1.20 billion, including 12+8 container feeder vessels, 2 offshore engineering special vessels and other module orders. As of the end of 2025, the accumulated value of orders on hand reached US$5.09 billion, with orders for oil & gas and special vessel accounting for approximately 70% and 30%, respectively. The Longkou base has scheduled production through to 2030.In the offshore engineering asset operation and management business, the Group continued to leverage its existing project experience and business capabilities, enhancing asset utilisation through its strong offshore platform operation and management capabilities. During the Reporting Period, the sixth-generation semi-submersible drilling platform “Deepsea Yantai” completed lease renewal, the ultra-deepwater semi-submersible drilling platform “Blue Whale No.1” signed a new lease with an international client, and the semi-submersible lifting/life platform “Blue Gretha (formerly Huadian CIMC 01)” also secured a new lease with an international client. Other platforms actively participated in market tenders to explore opportunities for asset disposal and leasing. During the Reporting Period, the average daily lease rate of semi-submersible and jack-up drilling platforms both recorded year-on-year increases.Future Development and ProspectsThe Group’s management stated, “The year 2026 marks the beginning of the ‘15th Five-Year Plan’. Starting from a newly upgraded brand identity, the Group will closely focus on ‘consolidating foundations, driving innovation, improving quality and efficiency’, and adopt a more proactive strategic approach to foster new opportunities and open new horizons amid complex changes, striving to build a ‘“becoming a high quality and trustworthy world-class multimodal transport enterprise.”About China International Marine Containers (Group) Co., Ltd.The CIMC Group is a world-leading equipment and solution provider in the logistics and energy industries, with its industry clusters mainly covering the logistics and energy fields, continuously strengthening its leading market position. In the logistics field, the Group continues to adhere to container manufacturing as its core business, based on which it has incubated the road transportation vehicles business and the airport facilities and logistics equipment / fire safety and rescue equipment business, supplemented by the logistics services business and recycled load business, providing products and services in the professional logistics field. In the energy field, the Group is principally engaged in the energy, chemical and liquid food equipment business and the offshore engineering business. Meanwhile, the Group continues to develop emerging industries and possesses financial and asset management businesses that serve the Group itself. As a diversified multinational industrial group serving the global market, CIMC has over 300 member enterprises across Asia, North America, Europe, and Australia, with a total of four listed companies, and customers and sales networks covering more than 100 countries and regions worldwide. In 2025, the Group recorded revenue of RMB 156.6 billion, ranking 154th on the 2025 Fortune 500 China list. The Group has maintained the world’s No.1 position for many consecutive years in core products such as standard dry containers, reefer containers, tank containers and semi-trailers. For more information, please visit http://www.cimc.com/. Copyright 2026 ACN Newswire. All rights reserved. www.acnnewswire.com